60 Degrees Pharmaceuticals, Inc.
SXTP
$0.97
-$0.01-0.68%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 199.73% | 126.18% | 115.43% | 164.39% | 123.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 199.73% | 126.18% | 115.43% | 164.39% | 123.55% |
| Cost of Revenue | -92.80% | -87.32% | 284.03% | 390.63% | 214.62% |
| Gross Profit | 129.57% | 115.69% | -406.69% | -529.29% | -231.57% |
| SG&A Expenses | 25.45% | 17.48% | 24.09% | 18.46% | 78.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.25% | -7.40% | 87.46% | 92.24% | 141.04% |
| Operating Income | 17.05% | 13.83% | -85.60% | -88.68% | -141.92% |
| Income Before Tax | -0.31% | -383.21% | -1,201.94% | -108.61% | -131.35% |
| Income Tax Expenses | 55.56% | 100.00% | -25.00% | -25.00% | -- |
| Earnings from Continuing Operations | -0.32% | -383.14% | -1,201.65% | -108.60% | -131.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -82.90% | -86.13% | -87.01% | -82.12% | 338.64% |
| Net Income | -0.72% | -397.33% | -1,294.74% | -111.03% | -130.84% |
| EBIT | 17.05% | 13.83% | -85.60% | -88.68% | -141.92% |
| EBITDA | 17.45% | 14.16% | -86.05% | -89.55% | -143.81% |
| EPS Basic | 87.46% | -327.84% | 49.58% | 79.57% | 69.08% |
| Normalized Basic EPS | 87.27% | 83.29% | 68.84% | 83.52% | 75.63% |
| EPS Diluted | 87.46% | -327.84% | 49.58% | 79.57% | 69.08% |
| Normalized Diluted EPS | 87.27% | 83.29% | 68.84% | 83.52% | 75.63% |
| Average Basic Shares Outstanding | 671.55% | 652.31% | 642.03% | 586.43% | 361.67% |
| Average Diluted Shares Outstanding | 671.55% | 652.31% | 642.03% | 586.43% | 361.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |